Justin Zelin
Stock Analyst at BTIG
(1.75)
# 3,366
Out of 5,090 analysts
43
Total ratings
31.71%
Success rate
-7.28%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Zelin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRSN Mersana Therapeutics | Downgrades: Neutral | n/a | $27.78 | - | 1 | Nov 13, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Buy | $50 | $32.88 | +52.07% | 1 | Nov 10, 2025 | |
| TCRX TScan Therapeutics | Downgrades: Neutral | n/a | $1.08 | - | 2 | Nov 4, 2025 | |
| IPHA Innate Pharma | Reiterates: Buy | $8 | $1.89 | +323.28% | 1 | Oct 29, 2025 | |
| SNDX Syndax Pharmaceuticals | Reiterates: Buy | $56 | $20.32 | +175.59% | 4 | Oct 27, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $62 | $35.87 | +72.85% | 3 | Oct 21, 2025 | |
| CAN Canaan | Reiterates: Buy | $8 | $0.93 | +756.90% | 1 | Oct 14, 2025 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $125 | $38.55 | +224.25% | 5 | Sep 22, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $20 → $7 | $1.71 | +309.36% | 3 | Sep 22, 2025 | |
| VSTM Verastem | Reiterates: Buy | $20 | $10.36 | +93.05% | 2 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.29 | +162.01% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $21.81 | +92.57% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.27 | - | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,000 → $800 | $1.25 | +63,900.00% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $91 | $38.78 | +134.66% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $0.53 | +1,771.96% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $2.34 | +583.76% | 1 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $28.13 | +219.94% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $11.95 | +159.41% | 1 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $16 | $47.86 | -67.61% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $10 | $0.96 | +941.56% | 3 | Nov 16, 2022 |
Mersana Therapeutics
Nov 13, 2025
Downgrades: Neutral
Price Target: n/a
Current: $27.78
Upside: -
Ascentage Pharma Group International
Nov 10, 2025
Initiates: Buy
Price Target: $50
Current: $32.88
Upside: +52.07%
TScan Therapeutics
Nov 4, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.08
Upside: -
Innate Pharma
Oct 29, 2025
Reiterates: Buy
Price Target: $8
Current: $1.89
Upside: +323.28%
Syndax Pharmaceuticals
Oct 27, 2025
Reiterates: Buy
Price Target: $56
Current: $20.32
Upside: +175.59%
IDEAYA Biosciences
Oct 21, 2025
Reiterates: Buy
Price Target: $62
Current: $35.87
Upside: +72.85%
Canaan
Oct 14, 2025
Reiterates: Buy
Price Target: $8
Current: $0.93
Upside: +756.90%
Viking Therapeutics
Sep 22, 2025
Reiterates: Buy
Price Target: $125
Current: $38.55
Upside: +224.25%
Jasper Therapeutics
Sep 22, 2025
Maintains: Buy
Price Target: $20 → $7
Current: $1.71
Upside: +309.36%
Verastem
Sep 9, 2025
Reiterates: Buy
Price Target: $20
Current: $10.36
Upside: +93.05%
Jan 10, 2025
Initiates: Buy
Price Target: $6
Current: $2.29
Upside: +162.01%
Dec 13, 2024
Initiates: Buy
Price Target: $42
Current: $21.81
Upside: +92.57%
May 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $4.27
Upside: -
Aug 15, 2023
Maintains: Buy
Price Target: $1,000 → $800
Current: $1.25
Upside: +63,900.00%
Aug 11, 2023
Maintains: Buy
Price Target: $85 → $91
Current: $38.78
Upside: +134.66%
Aug 10, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $0.53
Upside: +1,771.96%
Jul 25, 2023
Initiates: Buy
Price Target: $16
Current: $2.34
Upside: +583.76%
Jun 13, 2023
Maintains: Buy
Price Target: $85 → $90
Current: $28.13
Upside: +219.94%
May 17, 2023
Initiates: Buy
Price Target: $31
Current: $11.95
Upside: +159.41%
Mar 28, 2023
Maintains: Buy
Price Target: $10 → $16
Current: $47.86
Upside: -67.61%
Nov 16, 2022
Maintains: Buy
Price Target: $21 → $10
Current: $0.96
Upside: +941.56%